Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 6/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 1/20 | 0.33 |
| ▸ | GRM6 | O15303 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25025784 | 0.82 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL30233576 | 0.82 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL25024421 | 0.82 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL17461457 | 0.81 | POLB (0.36) | KDM4EHPGDSPOLB | |
| SCHEMBL14809937 | 0.81 | POLB (0.36) | KDM4EHPGDSPOLB | |
| SCHEMBL18987902 | 0.81 | POLB (0.36) | KDM4EHPGDSPOLB | |
| SCHEMBL21227457 | 0.80 | ALOX15 (0.42) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL77511 | 0.77 | RECQL (0.55) | ATMALDH1A1KDM4EPOLB | |
| SCHEMBL16614406 | 0.77 | ATM (0.39) | ATMALDH1A1KDM4EALOX15MTNR1A | |
| SCHEMBL6604915 | 0.77 | ATM (0.39) | ATMALDH1A1KDM4EALOX15MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118922421-A | Bicyclic phthalazin-1 (2H) -one derivatives and related uses | 诺瑟拉有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | TENVIE THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| CN-116507608-A | Compounds, compositions, and methods | 戴纳立制药公司 | 2023-07-28 | — | — | CN | disclosed |
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| EP-4143192-A1 | NEW TRIAZINOINDOLE COMPOUNDS | JANSSEN Pharmaceutica NV (BE) | 2023-03-08 | — | — | EP | disclosed |
| WO-2022271749-A1 | HETEROCYCLIC EGFR INHIBITORS FOR USE IN THE TREATMENT OF CANCER | BLUEPRINT MEDICINES CORPORATION (US) | 2022-12-29 | — | — | WO | disclosed |
| CN-114907341-A | Pyridopyrimidinone derivatives, and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-08-16 | — | — | CN | disclosed |
| WO-2016177686-A1 | PYRIDAZINE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2016-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357162-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | ATM 3268/4885ALDH1A1 4692/4885KDM4E 3928/4885 |
| US-20230348437-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | NLRP3, NLRP1, NOD1 | ATM 3268/4885ALDH1A1 4692/4885KDM4E 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.